BioCentury
ARTICLE | Company News

Acorda, Endo deal

February 8, 2016 8:00 AM UTC

Acorda granted Endo’s Par Pharmaceutical Inc. company rights to market a generic version of Acorda’s Ampyra dalfampridine for multiple sclerosis (MS) in 2027 or earlier. The license settles a patent ...